Evidence map›Paper›PMID 41915890›Full record

ArticleBlood advances2026

Digenic and multigenic heterozygous FHL genotypes are common but clinically silent in the general population.

Oleg Borisov, Jasmin Mann, Kevin Kim Walz, Florian Oyen, Helena Clara Lichtenfeld, Kai Lehmberg, Anna Köttgen, Stephan Ehl, Oliver Wegehaupt

Abstract read
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Oleg BorisovInstitute of Genetic Epidemiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0001-8700-4335
Jasmin MannInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-8934-0639
Kevin Kim WalzInstitute of Genetic Epidemiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Florian OyenDivision of Pediatric Stem Cell Transplantation and Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Helena Clara LichtenfeldDivision of Pediatric Stem Cell Transplantation and Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-7330-744X
Kai LehmbergDivision of Pediatric Stem Cell Transplantation and Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Anna KöttgenInstitute of Genetic Epidemiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-4671-3714
Stephan EhlInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-9265-2721
Oliver WegehauptInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0002-9391-0761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractPrimary hemophagocytic lymphohistiocytosis (HLH) is mainly caused by biallelic variants in genes disrupting cytotoxic natural killer (NK) cell and T-cell function (PRF1, UNC13D, STX11, STXBP2, RAB27A, and LYST). A "pathway defect accumulation" model proposes that heterozygous variants in multiple familial hemophagocytic lymphohistiocytosis (FHL) genes (digenic or multigenic inheritance) may increase susceptibility, but its significance remains debated. We assessed the prevalence and clinical relevance of digenic/multigenic FHL genotypes in a German FHL cohort (1987-2023) and the UK Biobank (UKB; 469 589 participants). We analyzed (1) variants classified as disease mutations in the Human Gene Mutation database (HGMD); (2) common variants such as PRF1 p.Ala91Val and p.Asn252Ser; and (3) additional variants previously reported in digenic HLH and explored phenotypic associations using codes of the International Classification of Diseases, 10th Revision for possible HLH-related conditions. In the German cohort, among 635 individuals sequenced for >1 FHL gene, no symptomatic patient with abnormal NK/cytotoxic T-lymphocyte degranulation carried digenic/multigenic heterozygous variants. In UKB, 575 individuals carried digenic FHL genotypes (0.1% prevalence), without enrichment for HLH-associated phenotypes (odds ratio, 0.95; P = 1). Four individuals carried trigenic genotypes; none had HLH-related diagnoses. Several HGMD-labeled pathogenic variants were observed biallelically in asymptomatic adults, suggesting potential misclassification. Including PRF1 p.Ala91Val and p.Asn252Ser increased digenic variant carriers to 2590 but did not cause phenotype enrichment. Digenic heterozygous FHL variants are relatively common in the general population but do not confer increased FHL risk. Many reported pathogenic FHL variants may be benign. These findings argue against classifying multigenic heterozygous carriers as at risk and support integrating population data into variant interpretation.

Indexed as

GenotypeHeterozygoteLymphohistiocytosis, HemophagocyticAdultAgedFemaleGenetic Predisposition to DiseaseGermanyHumansMaleMiddle AgedMutationPhenotype

Identifiers

PMID41915890
PMCPMC13207450

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.